AMEND news in Tag: MTC
-
Cryoablation of bone metastases in thyroid and adrenocortical cancers
This study looked at a minimally invasive treatment called cryoablation, which uses extreme cold to destroy cancer that has spread to the bones, in people with thyroid (including MTC) or adrenocortical cancer.
Click here for more information
-
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A
This study followed people with MEN2A who had their thyroid removed to understand how often long-term blood tests for calcitonin are really needed.
Click here for more information
-
The prostate is a common site of disease in patients with MEN2B and MTC
A recent study looked at young men with MEN2B (also known as MEN3), which causes medullary thyroid cancer. Doctors found that problems in the prostate were more common than previously thought, even in teenagers.
Click here for more information
-
National Cancer Plan for England Launched
Wednesday 4th February 2026, marked as World Cancer Day, saw the publication of the detailed National Cancer Plan for England by the Department of Health & Social Care
Click here to learn more
-
Rescheduled MTC Webinar Confirmed
We are pleased to confirm the new date for our rescheduled webinar on sporadic medullary thyroid cancer (spMTC). Come and join us on Wednesday 19th November, 2025, from 19:00-20:30, and hear from and quiz our esteemed expert medical speakers, Drs Kate Newbold and Daniel Morganstein from The Royal Marsden Hospital in London.
Click here for more information and to book
-
Webinar for Sporadic MTC Patients
AMEND is delighted to be hosting a free, live webinar for the sporadic medullary thyroid cancer (MTC) community on Wednesday 18th June from 19:00-20:30. Our expert speakers are Consultant Endocrinologist, Dr Daniel Morganstein, and Consultant Clinical Oncologist, Dr Kate Newbold, both from the Royal Marsden Hospital in London. We hope you can join us.
Click here to register
-
Selpercatinib – Can you Help?
AMEND is preparing a patient group submission for the Scottish Medicine's Consortium for the assessment of selpercatinib for use in metastatic MTC with the hope of getting it approved. Can you help us by sending us your input?
Click here for more information
-
Annual Patient Information Day Booking Open
The 2025 AMEND Annual Patient Information Day will be held on Saturday 31st May in central London. Disease-specific Q&A sessions with medical experts will be held in the morning and followed by other useful and topical sessions throughout the day. This event is FREE.
Click here for more information and to book
-
2024 Annual Patient Information Day
AMEND's 2024 Annual Patient Information Day will be held on Saturday 1st June, in central Birmingham. This event is open to anyone affected by MEN or PPGL syndromes, as well as for those affected by ACC and MTC. Come along and benefit from a 2-hour Q&A session with an expert in your disease, as well as plenty of other relevant sessions. There is a separate stream for young adults from 12 years of age. Tickets are available on a donation basis (minimum £1 per ticket).
Click here for more information and to book
-
NETS in RETS
November 10th each year is NET Cancer Day, initiated by the International Neuroendocrine Cancer Alliance, of which AMEND is a member representing genetic neuroendocrine tumour syndromes. To better explain the link between NETs and RETS (rare endocrine tumours and syndromes), join us for our webinar, NETs in RETS, with Professor Karim Meeran on Thursday 9th November from 18:00-19:00.
Click here for more information